Comparative pharmacokinetics of new anti-HIV agents: 2', 3'-dideoxyadenosine and 2', 3'-dideoxyinosine
- 1 May 1989
- journal article
- research article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 38 (9), 1385-1388
- https://doi.org/10.1016/0006-2952(89)90176-7
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Inhibition of HIV reverse transcriptase by 2′,3′-dideoxynucleoside triphosphatesBiochemical Pharmacology, 1987
- Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivityBiochemical Pharmacology, 1987
- THE DISPOSITION AND METABOLISM OF 2',3'-DIDEOXYCYTIDINE, AN INVITRO INHIBITOR OF HUMAN T-LYMPHOTROPHIC VIRUS TYPE-III INFECTIVITY, IN MICE AND MONKEYS1987
- Strategies for antiviral therapy in AIDSNature, 1987
- Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.Proceedings of the National Academy of Sciences, 1986
- Specificity of adenosine deaminase toward adenosine and 2′-deoxyadenosine analoguesArchives of Biochemistry and Biophysics, 1966